Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173169 · ClinicalTrials.gov registry record · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT04173169: Completed Phase 3 study, sponsored by Yale University.
NCT04173169 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 103 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04173169, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Primary Outcome
The percentage of the number of participants with a live birth at ≥24 weeks of gestation out of those who were enrolled in the study
Interventions
- DRUG Elagolix 200 MG
- OTHER Placebo or SOC IVF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 3 |
What the finished NCT04173169 record still lists
NCT04173169 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Elagolix 200 MG is the first listed.
NCT04173169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04173169 about?
NCT04173169 is a clinical study titled "Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis". A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET...
What is the current status of trial NCT04173169?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2022-03-15. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT04173169?
The interventions under investigation include: Elagolix 200 MG (DRUG), Placebo or SOC IVF (OTHER).
Who is sponsoring clinical trial NCT04173169?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04173169's enrollment target sits among peer trials
103 1674th of 2000 higher than 325 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI